Drugs / NasoVAX
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04442230 | Oct 2020 → Feb 2021 | COVID-19 | Altimmune, Inc. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT03232567 | Sep 2017 → Mar 2018 | influenza | Altimmune, Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2019-04-11 | Altimmune, Inc. | Results Altimmune To Present NasoVAX Phase 2 Data at the World Vaccine Congress in Washington, D.C. altimmune.com ↗
These new NasoVAX data, obtained from the group of 8 subjects that returned for analysis show that the immune response elicited by NasoVAX remained at seroprotective levels for at least 13 months. |
| 2019-03-19 | Altimmune, Inc. | Results Altimmune Announces Positive Results from NasoVAX Extension Study altimmune.com ↗
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced additional positive data from a Phase 2 extension study of its NasoVAX intranasal influenza vaccine candidate. |
| 2018-09-04 | Altimmune, Inc. | Results Altimmune Announces Additional Positive Data from Its Phase 2a Study of NasoVAX Intranasal Influenza Vaccine altimmune.com ↗
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced additional positive data from a Phase 2a study of its NasoVAX intranasal influenza vaccine candidate. |
| 2018-03-27 | Altimmune, Inc. | Results Altimmune Announces Positive Data From Its Phase 2a Study of NasoVAX Intranasal Influenza Vaccine and Provides an Update on Its Phase 1b Study of HepTcell Targeted Immunotherapy in Chronic Hepatitis B Infection altimmune.com ↗
Results from the Phase 2a study of NasoVAX™ intranasal flu vaccine in 60 healthy individuals showed 100% seroprotection in the mid- and high-dose groups. |
| 2017-08-21 | Altimmune, Inc. | Regulatory Altimmune Submits Investigational New Drug Application for NasoVAX in Preparation for Phase 2 Trial altimmune.com ↗
Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, today announced the Company has submitted an Investigational New Drug (IND) application to the U.S Food and Drug Administration (FDA) for NasoVAX, the Company’s intranasally administered recombinant flu vaccine. |
All press releases naming this drug 6 releases
| Date | Issuer | Release |
|---|---|---|
| 2019-04-11 | Altimmune, Inc. | Altimmune To Present NasoVAX Phase 2 Data at the World Vaccine Congress in Washington, D.C. altimmune.com ↗ |
| 2019-03-19 | Altimmune, Inc. | Altimmune Announces Positive Results from NasoVAX Extension Study altimmune.com ↗ |
| 2018-09-04 | Altimmune, Inc. | Altimmune Announces Additional Positive Data from Its Phase 2a Study of NasoVAX Intranasal Influenza Vaccine altimmune.com ↗ |
| 2018-03-27 | Altimmune, Inc. | Altimmune Announces Positive Data From Its Phase 2a Study of NasoVAX Intranasal Influenza Vaccine and Provides an Update on Its Phase 1b Study of HepTcell Targeted Immunotherapy in Chronic Hepatitis B Infection altimmune.com ↗ |
| 2017-09-20 | Altimmune, Inc. | Altimmune Announces its Phase 2 Flu Vaccine Trial with NasoVAX Open for Enrollment altimmune.com ↗ |
| 2017-08-21 | Altimmune, Inc. | Altimmune Submits Investigational New Drug Application for NasoVAX in Preparation for Phase 2 Trial altimmune.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NasoVAX | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03232567 ↗ |
| Route | Intranasal | “NasoVAX administered by intranasal spray at a single dose of 1×10(9th) viral particles (vp) versus placebo” NCT03232567 ↗ |